Anurag Saraf

Dr. Anurag Saraf

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2022 in Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
ASAnurag Saraf
Anurag Saraf
TYTorunn I Yock
Torunn I Yock
ANAndrzej Niemierko
Andrzej Niemierko
KOKevin S Oh
Kevin S Oh
WCWilliam T Curry
William T Curry
HSHelen A. Shih
Helen A. Shih
Background: Medulloblastoma (MB) is a rare central nervous system malignancy of adults, with limited contemporary studies to define treatment guidelines and expected late toxicity. Methods: A single-center, retrospective study was conducted of patients age ≥18 years from 1997–2019 with MB and who were treated with postoperative radiotherapy. Late toxicity was defined as a minimum of 18 months from diagnosis. Overall survival (OS) and progression-free survival (PFS) were characterized using Kaplan-Meier and Cox regression analyses. Results: Fifty-nine patients met criteria, with median age of 25 years (range 18–62 y) and median follow-up of 6.5 years (range 0.7–23.1 y). At diagnosis, 68% were standard-risk, 88% Chang M0, and 22% with anaplastic histology. Gross total resection was achieved in 75%; median craniospinal irradiation dose was 30.6 Gy (relative biological effectiveness [RBE]), median total dose was 54.0 Gy (RBE), 80% received proton radiotherapy; 81% received chemotherapy. 5 year PFS and OS were 86.5% and 95.8%, respectively; 10 year PFS and OS were 83.9% and 90.7%, respectively. Anaplastic histology was associated with worse PFS (P = .04). Among eight recurrences, 25% presented after 5 years. Most common grade ≥2 late toxicities were anxiety/depressive symptoms (30%), motor dysfunction (25%), and ototoxicity (22%). Higher posterior fossa radiation dose was associated with increased risk of late toxicity, including worse cognitive dysfunction (P = .05). Conclusions: Adults with MB have favorable survival outcomes, but late failures and toxicity are not uncommon. Better understanding of prognostic factors, possibly from molecular subtyping, may help to define more personalized treatments for patients with high risk of recurrence and long-term treatment sequelae.

27 July 2023 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
ASAnurag Saraf
Anurag Saraf
ITIsmail Tahir
Ismail Tahir
BHBonnie Hu
Bonnie Hu
ADAnna-Sophia W. Dietrich
Anna-Sophia W. Dietrich
PTP. Erik Tonnesen
P. Erik Tonnesen
RJRachel B. Jimenez
Rachel B. Jimenez

3 March 2022 in Neurosurgery
Verified
Journal Article
Closed access
ASAnurag Saraf
Anurag Saraf
LPLuke R. G. Pike
Luke R. G. Pike
KFKevin H. Franck
Kevin H. Franck
NHNora K. Horick
Nora K. Horick
BYBeow Y. Yeap
Beow Y. Yeap
HSHelen A. Shih
Helen A. Shih
BACKGROUND: Local management for vestibular schwannoma (VS) is associated with excellent local control with focus on preserving long-term serviceable hearing. Fractionated proton radiation therapy (FPRT) may be associated with greater hearing preservation because of unique dosimetric properties of proton radiotherapy. OBJECTIVE: To investigate hearing preservation rates of FPRT in adults with VS and secondarily assess local control and treatment-related toxicity. METHODS: A prospective, single-arm, phase 2 clinical trial was conducted of patients with VS from 2010 to 2019. All patients had serviceable hearing at baseline and received FPRT to a total dose of 50.4 to 54 Gy relative biological effectiveness (RBE) over 28 to 30 fractions. Serviceable hearing preservation was defined as a Gardner–Robertson score of 1 to 2, measured by a pure tone average (PTA) of ≤50 dB and a word recognition score (WRS) of ≥50%. RESULTS: Twenty patients had a median follow-up of 4.0 years (range 1.0-5.0 years). Local control at 4 years was 100%. Serviceable hearing preservation at 1 year was 53% (95% CI 29%-76%), and primary end point was not yet reached. Median PTA and median WRS both worsened 1 year after FPRT (P < .0001). WRS plateaued after 6 months, whereas PTA continued to worsen up to 1 year after FPRT. Median cochlea D90 was lower in patients with serviceable hearing at 1 year (40.6 Gy [RBE] vs 46.9 Gy [RBE]), trending toward Wilcoxon rank-sum test statistical significance (P = .0863). Treatment was well-tolerated, with one grade 1 cranial nerve V dysfunction and no grade 2+ cranial nerve dysfunction. CONCLUSION: FPRT for VS did not meet the goal of serviceable hearing preservation. Higher cochlea doses trended to worsening hearing preservation, suggesting that dose to cochlea correlates with hearing preservation independent of treatment modality.

26 January 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
IEIlana B. Epstein
Ilana B. Epstein
AOAdetolani Odogiyon
Adetolani Odogiyon
SBStephanie Ann Berg
Stephanie Ann Berg
YOYukako Otani
Yukako Otani
CMCharlene Mantia
Charlene Mantia
KMKent W. Mouw
Kent W. Mouw
Purpose: Trimodality therapy (TMT) is a bladder-sparing treatment approach for patients with muscle-invasive bladder cancer (MIBC). Although plasma circulating tumor DNA (ctDNA) is correlated with treatment response and outcomes following cystectomy for MIBC, the association of plasma ctDNA with clinical outcomes in patients treated with TMT is poorly characterized. Experimental Design: Patients with MIBC who received TMT at Dana-Farber/Brigham and Women’s Cancer Center or Massachusetts General Hospital were consented to a research protocol and underwent ctDNA evaluation at baseline and at regular intervals following TMT using the commercially available Signatera assay. All patients also underwent routine post-TMT surveillance including cross-sectional imaging and cystoscopic evaluation. The association between ctDNA status and clinical disease status was assessed. Results: Eighty-four patients had at least one ctDNA result. Fifty-nine patients had a ctDNA test performed prior to chemoradiotherapy (CRT), and 19 (32%) had detectable ctDNA. Forty-six patients had paired pre- and post-CRT ctDNA results available: nearly all (29/31, 94%) patients with undetectable ctDNA prior to CRT also had undetectable ctDNA at the first post-CRT assessment, whereas 11 of 15 (73%) patients with detectable ctDNA prior to CRT converted to undetectable ctDNA following CRT. Sixteen (19%) patients developed metastatic disease, and detectable ctDNA following CRT was strongly correlated with metastatic recurrence (P < 0.0001). Conversely, no patients with an isolated muscle-invasive (n = 5) or non–muscle invasive (n = 7) bladder recurrence had a post-TMT test demonstrating detectable ctDNA prior to recurrence. Conclusions: ctDNA detectability is strongly correlated with metastatic but not local disease recurrence in patients with MIBC following TMT.

28 January 2025 in Clinical Lung Cancer
Verified
Journal Article
Closed access
ASAnurag Saraf
Anurag Saraf
JHJohn He
John He
KSKee-Young Shin
Kee-Young Shin
JWJakob Weiss
Jakob Weiss
MAMark M. Awad
Mark M. Awad
RMRaymond H. Mak
Raymond H. Mak

12 November 2024 in Cancers
Verified
Journal Article
Open access
PDF file
LTLeah Thompson
Leah Thompson
CFCaterina Florissi
Caterina Florissi
JYJaewon Yoon
Jaewon Yoon
ASAnupama Singh
Anupama Singh
ASAnurag Saraf
Anurag Saraf
Older adults with lung cancer experience inferior clinical outcomes compared to their younger counterparts. This review provides the scaffolding to address these disparities by delineating (1) the distinct and varied care needs of older adults with lung malignancies, (2) evidence-based measures for identifying subgroups within this population meriting tailored approaches to care, (3) age-specific considerations for the selection of cancer-directed therapy, and (4) opportunities for future work to enhance clinical outcomes and care delivery.